Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer

Gut

Volumn 65, Issue 8, 2016, Pages 1296-1305

  Kloth, Michael ^a   Ruesseler, Vanessa ^a   Engel, Christoph ^b   Koenig, Katharina ^a   Peifer, Martin ^c   Mariotti, Erika ^a   Kuenstlinger, Helen ^a   Florin, Alexandra ^a   Rommerscheidt Fuss, Ursula ^a   Koitzsch, Ulrike ^a   Wodtke, Claudia ^a   Ueckeroth, Frank ^a   Holzapfel, Stefanie ^d   Aretz, Stefan ^d   Propping, Peter ^d   Loeffler, Markus ^b   Merkelbach Bruse, Sabine ^a   Odenthal, Margarete ^a   Friedrichs, Nicolaus ^a   Heukamp, Lukas Carl ^a   Zander, Thomas ^a   Buettner, Reinhard ^a   more..

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; B RAF KINASE; CETUXIMAB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; K RAS PROTEIN; LAPATINIB; NERATINIB; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; SAPITINIB; SMALL INTERFERING RNA; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENE TARGETING; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LYNCH LIKE COLORECTAL CANCER; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE TECHNIQUE; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GENETICS; MIDDLE AGED; PATHOLOGY; PHARMACOGENETIC TESTING; PROCEDURES;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CETUXIMAB; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PHARMACOGENOMIC TESTING; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84930396495     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-309026     Document Type: Article

References (45)

1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
2. Pritchard CC, Grady WM. Colorectal cancer molecular biology moves into clinical practice. Gut 2011;60:116-29.
3. Cancer Genome Atlas Network. Comprehensive molecular characterisation of human colon and rectal cancer. Nature 2012;487:330-7.
4. Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54:1645-8.
5. Shih IM, Zhou W, Goodman SN, et al. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res 2001;61:818-22.
6. Loeb LA. Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 1994;54:5059-63.
7. Rijcken FE, Hollema H, Kleibeuker JH. Proximal adenomas in hereditary nonpolyposis colorectal cancer are prone to rapid malignant transformation. Gut 2002;50:382-6.
8. de la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 2010;28:3380-7.
9. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
10. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812-23.
11. Kravochuck SE, Kalady MF, Burke CA, et al. Defining HNPCC and Lynch syndrome: whats in a name? Gut 2014;63:1525-6.
12. Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: A literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012;49:151-7.
13. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-5.
14. Fang M, Ou J, Hutchinson L, et al. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype. Molecular Cell 2014;55:904-15.
15. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012;483: 100-3.
16. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010;26:589-95.
17. Kent WJ. BLAT-The BLAST-like alignment tool. Genome Res 2002;12:656-64.
18. Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009;25:2078-9.
19. Peifer M, Fernandez-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-10.
20. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14:178-92.
21. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123:1804-11.
22. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006;66:11341-7.
23. Kim TM, Laird PW, Park PJ. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 2013;155:858-68.
24. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: Application to cancer genomics. Nucleic Acids Res 2011;39:e118.
25. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483: 603-7.
26. Kancha RK, von Bubnoff N, Bartosch N, et al. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS ONE 2011;6:e26760.
27. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224-37.
28. Perez-Carbonell L, Ruiz-Ponte C, Guarinos C, et al. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Gut 2012;61: 865-72.
29. Heald B, Plesec T, Liu X, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol 2013;31:1336-40.
30. Salipante SJ, Scroggins SM, Hampel HL, et al. Microsatellite instability detection by next generation sequencing. Clinical Chemistry 2014;60:1192-9.
31. Lu Y, Soong TD, Elemento O. A novel approach for characterising microsatellite instability in cancer cells. PLoS One 2013;8:e63056.
32. Kim TM, Jung SH, Kim MS, et al. The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers. J Pathol 2014;234:365-74.
33. Tsao JL, Yatabe Y, Salovaara R, et al. Genetic reconstruction of individual colorectal tumor histories. Proc Natl Acad Sci USA 2000;97:1236-41.
34. Greenspan EJ, Cyr JL, Pleau DC, et al. Microsatellite instability in aberrant crypt foci from patients without concurrent colon cancer. Carcinogenesis 2007;28:769-76.
35. Oliveira C, Westra JL, Arango D, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics 2004;13:2303-11.
36. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.
37. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
38. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75.
39. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
40. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-Targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308-24.
41. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
42. Lee JW, Soung YH, Seo SH, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12:57-61.
43. Trowe T, Boukouvala S, Calkins K, et al. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 2008;14:2465-75.
44. Laforest A, Aparicio T, Zaanan A, et al. ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. Eur J Cancer 2014;50:1740-6
45. Cancer Genome Atlas Research Network. Comprehensive molecular characterisation of gastric adenocarcinoma. Nature 2014;513:202-9.